| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreaticoduodenectomy | 39 | 2023 | 509 | 4.210 |
Why?
|
| Pancreatectomy | 40 | 2023 | 811 | 3.510 |
Why?
|
| Pancreatic Fistula | 25 | 2022 | 148 | 3.170 |
Why?
|
| Pancreatic Neoplasms | 52 | 2022 | 5368 | 2.440 |
Why?
|
| Adenocarcinoma | 24 | 2021 | 6346 | 1.130 |
Why?
|
| Kupffer Cells | 13 | 2000 | 143 | 1.040 |
Why?
|
| Pancreatic Diseases | 9 | 2020 | 343 | 0.970 |
Why?
|
| Laparoscopy | 25 | 2015 | 2035 | 0.950 |
Why?
|
| Cholecystectomy, Laparoscopic | 12 | 2017 | 232 | 0.920 |
Why?
|
| Pancreatitis, Chronic | 4 | 2015 | 289 | 0.770 |
Why?
|
| Postoperative Complications | 38 | 2023 | 15631 | 0.710 |
Why?
|
| Bile Ducts | 5 | 2017 | 282 | 0.590 |
Why?
|
| NF-kappa B | 8 | 2006 | 2490 | 0.530 |
Why?
|
| Tumor Necrosis Factor-alpha | 10 | 2005 | 4352 | 0.520 |
Why?
|
| Apoptosis | 10 | 2006 | 9486 | 0.510 |
Why?
|
| Deoxycytidine | 3 | 2011 | 877 | 0.510 |
Why?
|
| Blood Loss, Surgical | 7 | 2021 | 637 | 0.500 |
Why?
|
| Gallbladder Neoplasms | 2 | 2017 | 189 | 0.490 |
Why?
|
| Triage | 2 | 2021 | 986 | 0.460 |
Why?
|
| Pancreas | 7 | 2020 | 1691 | 0.440 |
Why?
|
| Lipopolysaccharides | 10 | 2001 | 2206 | 0.440 |
Why?
|
| Multienzyme Complexes | 3 | 2002 | 666 | 0.430 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2020 | 954 | 0.430 |
Why?
|
| Carcinoma, Pancreatic Ductal | 5 | 2022 | 1727 | 0.430 |
Why?
|
| Decision Support Techniques | 6 | 2018 | 1998 | 0.430 |
Why?
|
| Boronic Acids | 4 | 2006 | 915 | 0.430 |
Why?
|
| I-kappa B Proteins | 4 | 2004 | 211 | 0.420 |
Why?
|
| Quality Indicators, Health Care | 6 | 2016 | 1792 | 0.410 |
Why?
|
| Bile Duct Diseases | 3 | 2015 | 97 | 0.390 |
Why?
|
| Pyrazines | 4 | 2006 | 1201 | 0.380 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 3 | 2001 | 435 | 0.380 |
Why?
|
| Dinoprostone | 7 | 1999 | 597 | 0.370 |
Why?
|
| Thioredoxins | 1 | 2012 | 202 | 0.370 |
Why?
|
| Pancreatic Cyst | 5 | 2017 | 367 | 0.360 |
Why?
|
| Biliary Tract Neoplasms | 3 | 2010 | 185 | 0.360 |
Why?
|
| Quality Assurance, Health Care | 3 | 2015 | 2169 | 0.350 |
Why?
|
| Sodium Salicylate | 2 | 1999 | 18 | 0.340 |
Why?
|
| Intraoperative Care | 2 | 2013 | 767 | 0.340 |
Why?
|
| Cysteine Endopeptidases | 3 | 2002 | 551 | 0.330 |
Why?
|
| Hospital Costs | 6 | 2018 | 947 | 0.330 |
Why?
|
| Gallstones | 5 | 2022 | 284 | 0.330 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2011 | 350 | 0.330 |
Why?
|
| Endotoxins | 3 | 1999 | 520 | 0.320 |
Why?
|
| Radiosurgery | 3 | 2017 | 1342 | 0.310 |
Why?
|
| Portacaval Shunt, Surgical | 5 | 1990 | 46 | 0.300 |
Why?
|
| Drainage | 8 | 2021 | 1157 | 0.300 |
Why?
|
| Cough | 2 | 2002 | 594 | 0.300 |
Why?
|
| Portal Vein | 9 | 2001 | 431 | 0.300 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2017 | 3514 | 0.300 |
Why?
|
| Risk Assessment | 27 | 2021 | 23995 | 0.300 |
Why?
|
| Cholangiography | 4 | 2013 | 181 | 0.290 |
Why?
|
| Pancreaticojejunostomy | 3 | 2013 | 26 | 0.290 |
Why?
|
| Pneumoperitoneum, Artificial | 6 | 2001 | 40 | 0.290 |
Why?
|
| Gastroesophageal Reflux | 4 | 2002 | 819 | 0.280 |
Why?
|
| Fundoplication | 3 | 2002 | 144 | 0.280 |
Why?
|
| Cholestasis | 3 | 2019 | 378 | 0.280 |
Why?
|
| Ubiquitin | 2 | 2002 | 839 | 0.280 |
Why?
|
| Endoscopy | 4 | 2021 | 1851 | 0.270 |
Why?
|
| Cell Nucleus | 3 | 2012 | 2909 | 0.270 |
Why?
|
| Hydroxamic Acids | 2 | 2006 | 481 | 0.270 |
Why?
|
| Humans | 151 | 2023 | 761504 | 0.260 |
Why?
|
| Propensity Score | 8 | 2021 | 1913 | 0.260 |
Why?
|
| Liver Transplantation | 9 | 2006 | 2330 | 0.260 |
Why?
|
| Patient Discharge | 4 | 2023 | 3443 | 0.250 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2010 | 646 | 0.250 |
Why?
|
| Duodenal Neoplasms | 2 | 2014 | 114 | 0.250 |
Why?
|
| Caspases | 2 | 2006 | 879 | 0.250 |
Why?
|
| Phosphatidylinositol 3-Kinases | 5 | 2001 | 2865 | 0.250 |
Why?
|
| Neoadjuvant Therapy | 5 | 2021 | 2827 | 0.250 |
Why?
|
| Risk Factors | 43 | 2023 | 74206 | 0.240 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2006 | 296 | 0.240 |
Why?
|
| Bile Duct Neoplasms | 2 | 2010 | 605 | 0.240 |
Why?
|
| Retrospective Studies | 49 | 2023 | 80636 | 0.230 |
Why?
|
| Critical Pathways | 2 | 2011 | 474 | 0.230 |
Why?
|
| Macrophages | 6 | 2001 | 5769 | 0.230 |
Why?
|
| Education, Medical, Continuing | 3 | 2021 | 823 | 0.230 |
Why?
|
| Octreotide | 4 | 2018 | 153 | 0.230 |
Why?
|
| Cholecystectomy | 4 | 2017 | 406 | 0.230 |
Why?
|
| Hepatitis | 1 | 2005 | 228 | 0.220 |
Why?
|
| Aged | 67 | 2023 | 169289 | 0.220 |
Why?
|
| Stents | 5 | 2018 | 3179 | 0.220 |
Why?
|
| Treatment Outcome | 41 | 2019 | 64680 | 0.220 |
Why?
|
| Tumor Cells, Cultured | 8 | 2004 | 6132 | 0.210 |
Why?
|
| Mitogen-Activated Protein Kinases | 4 | 2001 | 1246 | 0.210 |
Why?
|
| Male | 99 | 2023 | 360804 | 0.210 |
Why?
|
| Meat | 1 | 2006 | 584 | 0.210 |
Why?
|
| Postoperative Care | 2 | 2013 | 1468 | 0.210 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2005 | 1062 | 0.210 |
Why?
|
| Fishes | 1 | 2006 | 603 | 0.210 |
Why?
|
| Proteasome Endopeptidase Complex | 4 | 2002 | 1320 | 0.210 |
Why?
|
| Liver Neoplasms | 5 | 2005 | 4320 | 0.210 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3084 | 0.200 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3204 | 0.200 |
Why?
|
| Middle Aged | 74 | 2023 | 220895 | 0.200 |
Why?
|
| Female | 97 | 2023 | 392644 | 0.200 |
Why?
|
| Length of Stay | 15 | 2021 | 6425 | 0.200 |
Why?
|
| Emergencies | 2 | 2014 | 1217 | 0.200 |
Why?
|
| Macrophage Activation | 3 | 2000 | 553 | 0.190 |
Why?
|
| Interleukin-6 | 6 | 2000 | 3208 | 0.190 |
Why?
|
| Immunophilins | 1 | 2001 | 20 | 0.190 |
Why?
|
| Liver Regeneration | 3 | 1993 | 213 | 0.190 |
Why?
|
| Peptide Hydrolases | 2 | 2002 | 624 | 0.190 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2006 | 774 | 0.190 |
Why?
|
| Neoplasm Staging | 9 | 2017 | 11121 | 0.190 |
Why?
|
| Carcinoma | 1 | 2012 | 2330 | 0.180 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2001 | 203 | 0.180 |
Why?
|
| Liver | 19 | 2002 | 7529 | 0.180 |
Why?
|
| Patient Selection | 6 | 2020 | 4244 | 0.180 |
Why?
|
| Cholangiocarcinoma | 1 | 2006 | 552 | 0.180 |
Why?
|
| Islets of Langerhans Transplantation | 6 | 1990 | 740 | 0.180 |
Why?
|
| Pain, Postoperative | 3 | 2019 | 1739 | 0.170 |
Why?
|
| Immune Tolerance | 6 | 1991 | 2303 | 0.170 |
Why?
|
| Intraoperative Complications | 1 | 2006 | 1165 | 0.170 |
Why?
|
| Time Factors | 25 | 2018 | 39967 | 0.170 |
Why?
|
| Immunity, Cellular | 2 | 2004 | 1560 | 0.170 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2000 | 2273 | 0.170 |
Why?
|
| Fatty Liver | 1 | 2005 | 790 | 0.160 |
Why?
|
| Biliary Tract Surgical Procedures | 2 | 2016 | 45 | 0.160 |
Why?
|
| Multivariate Analysis | 10 | 2016 | 12059 | 0.160 |
Why?
|
| Survival Rate | 9 | 2019 | 12725 | 0.160 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 1999 | 188 | 0.160 |
Why?
|
| Inositol 1,4,5-Trisphosphate | 1 | 1999 | 110 | 0.160 |
Why?
|
| Cyclins | 1 | 2001 | 594 | 0.160 |
Why?
|
| Cecal Neoplasms | 1 | 2018 | 26 | 0.160 |
Why?
|
| Attitude of Health Personnel | 1 | 2012 | 3889 | 0.160 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 2 | 2012 | 194 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 1405 | 0.150 |
Why?
|
| Granular Cell Tumor | 1 | 2018 | 48 | 0.150 |
Why?
|
| General Surgery | 2 | 2007 | 1692 | 0.150 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 1996 | 1116 | 0.150 |
Why?
|
| Endoscopy, Digestive System | 1 | 2000 | 351 | 0.150 |
Why?
|
| Arginine | 3 | 1993 | 934 | 0.150 |
Why?
|
| Abdominal Muscles | 1 | 2019 | 169 | 0.150 |
Why?
|
| Pancreatic Pseudocyst | 2 | 2009 | 110 | 0.150 |
Why?
|
| Liver Circulation | 6 | 2002 | 159 | 0.150 |
Why?
|
| Carrier Proteins | 2 | 2001 | 4936 | 0.150 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1999 | 489 | 0.150 |
Why?
|
| Aged, 80 and over | 28 | 2022 | 58976 | 0.150 |
Why?
|
| Tissue and Organ Procurement | 1 | 2006 | 961 | 0.150 |
Why?
|
| Ubiquitins | 1 | 1999 | 366 | 0.150 |
Why?
|
| Cecum | 1 | 2018 | 233 | 0.150 |
Why?
|
| Antineoplastic Agents | 5 | 2017 | 13639 | 0.150 |
Why?
|
| Rats, Inbred WF | 10 | 1991 | 138 | 0.150 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 6 | 2010 | 506 | 0.140 |
Why?
|
| Pressure Ulcer | 1 | 2018 | 157 | 0.140 |
Why?
|
| Patient Readmission | 7 | 2023 | 3270 | 0.140 |
Why?
|
| Preoperative Care | 5 | 2009 | 2242 | 0.140 |
Why?
|
| Ischemic Preconditioning | 3 | 2002 | 89 | 0.140 |
Why?
|
| Rehabilitation Centers | 1 | 2018 | 246 | 0.140 |
Why?
|
| Rats | 23 | 2001 | 23742 | 0.140 |
Why?
|
| Ganglioneuroma | 1 | 1996 | 53 | 0.140 |
Why?
|
| Ampulla of Vater | 2 | 2007 | 149 | 0.140 |
Why?
|
| Protease Inhibitors | 3 | 2006 | 754 | 0.130 |
Why?
|
| Severity of Illness Index | 13 | 2016 | 15842 | 0.130 |
Why?
|
| Dexamethasone | 1 | 2003 | 1948 | 0.130 |
Why?
|
| Surgical Wound Infection | 2 | 2018 | 1527 | 0.130 |
Why?
|
| Enzyme Inhibitors | 5 | 2006 | 3712 | 0.130 |
Why?
|
| Isoantigens | 4 | 1991 | 551 | 0.130 |
Why?
|
| Constriction, Pathologic | 3 | 2015 | 1096 | 0.130 |
Why?
|
| Gastrointestinal Tract | 1 | 2022 | 833 | 0.130 |
Why?
|
| Cell Division | 5 | 2001 | 4465 | 0.130 |
Why?
|
| Gastrointestinal Stromal Tumors | 2 | 2014 | 617 | 0.130 |
Why?
|
| Common Bile Duct | 1 | 1995 | 106 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 7390 | 0.120 |
Why?
|
| Quality of Life | 1 | 2017 | 13367 | 0.120 |
Why?
|
| Islets of Langerhans | 6 | 2010 | 1341 | 0.120 |
Why?
|
| Celiac Artery | 1 | 2015 | 65 | 0.120 |
Why?
|
| Type C Phospholipases | 1 | 1995 | 287 | 0.120 |
Why?
|
| Carbon Dioxide | 3 | 2001 | 1147 | 0.120 |
Why?
|
| Graft Survival | 10 | 2006 | 3819 | 0.120 |
Why?
|
| Androstadienes | 1 | 1996 | 348 | 0.120 |
Why?
|
| Boston | 8 | 2018 | 9326 | 0.120 |
Why?
|
| Macrophages, Peritoneal | 1 | 1995 | 238 | 0.120 |
Why?
|
| Morbidity | 5 | 2019 | 1750 | 0.110 |
Why?
|
| Lymphoma, B-Cell | 1 | 2001 | 940 | 0.110 |
Why?
|
| CA-19-9 Antigen | 2 | 2011 | 106 | 0.110 |
Why?
|
| Hypersensitivity, Delayed | 3 | 1990 | 490 | 0.110 |
Why?
|
| Glucocorticoids | 1 | 2003 | 2161 | 0.110 |
Why?
|
| bcl-X Protein | 2 | 2006 | 410 | 0.110 |
Why?
|
| Prognosis | 8 | 2021 | 29625 | 0.110 |
Why?
|
| Infection Control | 1 | 2021 | 981 | 0.110 |
Why?
|
| Duodenal Diseases | 1 | 1994 | 100 | 0.110 |
Why?
|
| Health Expenditures | 2 | 2016 | 2366 | 0.110 |
Why?
|
| Pancreatitis | 3 | 2009 | 1096 | 0.110 |
Why?
|
| Health Services Accessibility | 2 | 2012 | 5440 | 0.110 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2017 | 1784 | 0.110 |
Why?
|
| Paraganglioma | 1 | 2014 | 142 | 0.110 |
Why?
|
| Biliary Tract Diseases | 2 | 2013 | 159 | 0.110 |
Why?
|
| Portal System | 2 | 1990 | 49 | 0.110 |
Why?
|
| Diverticulum | 1 | 1994 | 137 | 0.110 |
Why?
|
| Postoperative Hemorrhage | 1 | 2016 | 415 | 0.100 |
Why?
|
| Lipoma | 1 | 2014 | 293 | 0.100 |
Why?
|
| Hamartoma | 1 | 2014 | 235 | 0.100 |
Why?
|
| Signal Transduction | 5 | 2002 | 23445 | 0.100 |
Why?
|
| Phosphorylation | 6 | 2001 | 8320 | 0.100 |
Why?
|
| Quality Improvement | 2 | 2020 | 3801 | 0.100 |
Why?
|
| Adult | 38 | 2021 | 221177 | 0.100 |
Why?
|
| Florida | 3 | 2020 | 431 | 0.100 |
Why?
|
| Phosphoproteins | 1 | 2001 | 2448 | 0.100 |
Why?
|
| Nerve Block | 1 | 2019 | 706 | 0.100 |
Why?
|
| Immunity | 1 | 1998 | 996 | 0.100 |
Why?
|
| Language | 1 | 2021 | 1540 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2000 | 3810 | 0.100 |
Why?
|
| Reoperation | 5 | 2017 | 4303 | 0.100 |
Why?
|
| Enzyme Activation | 3 | 2004 | 3597 | 0.100 |
Why?
|
| Logistic Models | 7 | 2016 | 13255 | 0.100 |
Why?
|
| Cost Savings | 2 | 2007 | 913 | 0.100 |
Why?
|
| Drug Synergism | 2 | 2006 | 1755 | 0.100 |
Why?
|
| Animals | 44 | 2006 | 168459 | 0.090 |
Why?
|
| Indomethacin | 5 | 1993 | 325 | 0.090 |
Why?
|
| Odds Ratio | 5 | 2016 | 9646 | 0.090 |
Why?
|
| ROC Curve | 3 | 2015 | 3579 | 0.090 |
Why?
|
| Clinical Competence | 5 | 2020 | 4792 | 0.090 |
Why?
|
| Anastomosis, Surgical | 3 | 2021 | 983 | 0.090 |
Why?
|
| Drug Administration Schedule | 3 | 2019 | 4853 | 0.090 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 1410 | 0.090 |
Why?
|
| Drug Tolerance | 3 | 1999 | 367 | 0.090 |
Why?
|
| United States | 17 | 2019 | 72334 | 0.090 |
Why?
|
| Mitogens | 2 | 2001 | 230 | 0.090 |
Why?
|
| Hypoglycemia | 2 | 2010 | 883 | 0.090 |
Why?
|
| Colorectal Neoplasms | 3 | 2006 | 6935 | 0.090 |
Why?
|
| Peritoneum | 2 | 2004 | 225 | 0.090 |
Why?
|
| Receptors, Glucagon | 1 | 2010 | 90 | 0.090 |
Why?
|
| Societies, Medical | 2 | 2020 | 3905 | 0.090 |
Why?
|
| Combined Modality Therapy | 6 | 2011 | 8529 | 0.090 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2015 | 572 | 0.090 |
Why?
|
| Ultrasonography | 4 | 2012 | 5972 | 0.090 |
Why?
|
| Chi-Square Distribution | 4 | 2019 | 3416 | 0.090 |
Why?
|
| Perioperative Care | 3 | 2012 | 1033 | 0.090 |
Why?
|
| Hepatectomy | 5 | 2001 | 557 | 0.090 |
Why?
|
| Survival Analysis | 5 | 2015 | 10090 | 0.080 |
Why?
|
| Databases, Factual | 7 | 2019 | 7967 | 0.080 |
Why?
|
| Leiomyoma | 1 | 2014 | 636 | 0.080 |
Why?
|
| Gastric Bypass | 2 | 2010 | 818 | 0.080 |
Why?
|
| Nomograms | 1 | 2011 | 230 | 0.080 |
Why?
|
| Blotting, Western | 4 | 2000 | 5035 | 0.080 |
Why?
|
| Efficiency | 1 | 2012 | 476 | 0.080 |
Why?
|
| Evidence-Based Medicine | 2 | 2020 | 3688 | 0.080 |
Why?
|
| S Phase | 2 | 2001 | 421 | 0.080 |
Why?
|
| Incidental Findings | 2 | 2017 | 697 | 0.080 |
Why?
|
| G1 Phase | 2 | 2001 | 403 | 0.080 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2010 | 213 | 0.080 |
Why?
|
| Amylases | 1 | 2009 | 171 | 0.080 |
Why?
|
| Spleen | 6 | 1993 | 2295 | 0.080 |
Why?
|
| Abdominal Pain | 1 | 2015 | 1071 | 0.080 |
Why?
|
| Mucins | 1 | 2012 | 568 | 0.080 |
Why?
|
| Cause of Death | 2 | 2017 | 3683 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2005 | 11742 | 0.080 |
Why?
|
| Cell Cycle | 3 | 2002 | 2932 | 0.080 |
Why?
|
| Models, Economic | 2 | 2016 | 716 | 0.080 |
Why?
|
| Gastrointestinal Agents | 2 | 2018 | 510 | 0.080 |
Why?
|
| Pancreatic Ducts | 1 | 2010 | 329 | 0.080 |
Why?
|
| Credentialing | 1 | 2009 | 116 | 0.080 |
Why?
|
| Predictive Value of Tests | 9 | 2018 | 15266 | 0.080 |
Why?
|
| Tomography, Spiral Computed | 1 | 2010 | 273 | 0.080 |
Why?
|
| Neuroendocrine Tumors | 1 | 2014 | 641 | 0.080 |
Why?
|
| Consensus | 2 | 2021 | 3123 | 0.080 |
Why?
|
| Pulmonary Alveoli | 1 | 1991 | 652 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 11 | 2012 | 20570 | 0.070 |
Why?
|
| Aspirin | 1 | 2000 | 3133 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2017 | 6484 | 0.070 |
Why?
|
| Gallbladder Diseases | 1 | 2009 | 141 | 0.070 |
Why?
|
| Phagocytosis | 3 | 1990 | 1528 | 0.070 |
Why?
|
| Diet | 1 | 2006 | 8075 | 0.070 |
Why?
|
| Palliative Care | 2 | 2019 | 3598 | 0.070 |
Why?
|
| Follow-Up Studies | 10 | 2021 | 39106 | 0.070 |
Why?
|
| Duodenal Ulcer | 1 | 2007 | 121 | 0.070 |
Why?
|
| Delirium | 1 | 2019 | 1668 | 0.070 |
Why?
|
| Hyperinsulinism | 1 | 2010 | 400 | 0.070 |
Why?
|
| Flavonoids | 2 | 2001 | 445 | 0.070 |
Why?
|
| Prospective Studies | 10 | 2023 | 54425 | 0.070 |
Why?
|
| Sensitivity and Specificity | 5 | 2007 | 14666 | 0.070 |
Why?
|
| Protein Kinase C | 2 | 2002 | 1202 | 0.070 |
Why?
|
| Cell Line | 5 | 2004 | 15601 | 0.070 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2001 | 687 | 0.070 |
Why?
|
| Costs and Cost Analysis | 2 | 2015 | 1668 | 0.070 |
Why?
|
| Cryopreservation | 2 | 2002 | 728 | 0.070 |
Why?
|
| Models, Biological | 4 | 2012 | 9469 | 0.070 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2007 | 120 | 0.070 |
Why?
|
| Linear Models | 2 | 2013 | 5871 | 0.060 |
Why?
|
| Kinetics | 5 | 1996 | 6374 | 0.060 |
Why?
|
| Incidence | 6 | 2021 | 21353 | 0.060 |
Why?
|
| Quality of Health Care | 1 | 2020 | 4330 | 0.060 |
Why?
|
| Cell Separation | 3 | 2000 | 1720 | 0.060 |
Why?
|
| Health Care Surveys | 1 | 2012 | 2426 | 0.060 |
Why?
|
| Angiography | 2 | 2007 | 1595 | 0.060 |
Why?
|
| Quinones | 1 | 2005 | 78 | 0.060 |
Why?
|
| Hospitals, University | 1 | 2007 | 563 | 0.060 |
Why?
|
| Analgesics, Opioid | 2 | 2019 | 3808 | 0.060 |
Why?
|
| Cholecystitis | 1 | 2005 | 180 | 0.060 |
Why?
|
| User-Computer Interface | 3 | 2007 | 1400 | 0.060 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 3461 | 0.060 |
Why?
|
| Health Care Costs | 2 | 2015 | 3242 | 0.060 |
Why?
|
| Blood Vessels | 2 | 2010 | 1113 | 0.060 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2012 | 1007 | 0.060 |
Why?
|
| Population Surveillance | 1 | 2015 | 2598 | 0.060 |
Why?
|
| Cells, Cultured | 7 | 2001 | 18965 | 0.060 |
Why?
|
| Ribonucleotide Reductases | 1 | 2004 | 76 | 0.060 |
Why?
|
| Analgesia, Epidural | 1 | 2008 | 332 | 0.060 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2009 | 487 | 0.060 |
Why?
|
| Benzoquinones | 1 | 2005 | 198 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2006 | 426 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-rel | 1 | 2004 | 71 | 0.060 |
Why?
|
| Radiotherapy Dosage | 1 | 2011 | 2898 | 0.060 |
Why?
|
| Cell Line, Tumor | 3 | 2006 | 16981 | 0.060 |
Why?
|
| Swine | 10 | 2002 | 5915 | 0.060 |
Why?
|
| Massachusetts | 4 | 2021 | 8830 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2000 | 8181 | 0.060 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2005 | 192 | 0.060 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2004 | 103 | 0.060 |
Why?
|
| Sirolimus | 2 | 2001 | 1533 | 0.060 |
Why?
|
| Adenoma | 1 | 2014 | 2160 | 0.060 |
Why?
|
| Salvage Therapy | 1 | 2010 | 1264 | 0.060 |
Why?
|
| Age Factors | 5 | 2017 | 18395 | 0.060 |
Why?
|
| Biopsy | 2 | 2009 | 6766 | 0.060 |
Why?
|
| Decision Making | 1 | 2017 | 3929 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2005 | 17904 | 0.050 |
Why?
|
| Lactams, Macrocyclic | 1 | 2005 | 318 | 0.050 |
Why?
|
| Hernia, Inguinal | 2 | 1996 | 220 | 0.050 |
Why?
|
| Transcription Factor RelA | 1 | 2004 | 254 | 0.050 |
Why?
|
| Risk Adjustment | 2 | 2017 | 600 | 0.050 |
Why?
|
| Escherichia coli | 2 | 1996 | 4217 | 0.050 |
Why?
|
| Endosonography | 1 | 2006 | 609 | 0.050 |
Why?
|
| Educational Measurement | 2 | 2009 | 1254 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2002 | 2425 | 0.050 |
Why?
|
| RNA, Neoplasm | 1 | 2005 | 750 | 0.050 |
Why?
|
| Pain Measurement | 4 | 2019 | 3550 | 0.050 |
Why?
|
| Gastric Acidity Determination | 1 | 2002 | 56 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2019 | 22176 | 0.050 |
Why?
|
| Cohort Studies | 8 | 2021 | 41487 | 0.050 |
Why?
|
| Patient-Centered Care | 1 | 2012 | 1421 | 0.050 |
Why?
|
| Caspase 3 | 1 | 2004 | 731 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2011 | 1661 | 0.050 |
Why?
|
| Health Services Needs and Demand | 2 | 2016 | 1403 | 0.050 |
Why?
|
| Transplantation, Autologous | 4 | 1997 | 2115 | 0.050 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2005 | 424 | 0.050 |
Why?
|
| Liver Diseases | 2 | 1995 | 1298 | 0.050 |
Why?
|
| Bacterial Infections | 1 | 1990 | 1390 | 0.050 |
Why?
|
| Neoplasm Metastasis | 2 | 2005 | 4915 | 0.050 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2006 | 1118 | 0.050 |
Why?
|
| Tuftsin | 1 | 1981 | 4 | 0.050 |
Why?
|
| Immunoblotting | 1 | 2004 | 1646 | 0.050 |
Why?
|
| Peptide Initiation Factors | 1 | 2001 | 55 | 0.050 |
Why?
|
| Regression Analysis | 3 | 2016 | 6343 | 0.050 |
Why?
|
| Vascular Surgical Procedures | 1 | 2010 | 1489 | 0.050 |
Why?
|
| Rats, Inbred Lew | 7 | 1991 | 1157 | 0.050 |
Why?
|
| Fetal Proteins | 1 | 2001 | 98 | 0.050 |
Why?
|
| Immunoglobulin Fragments | 1 | 1981 | 84 | 0.050 |
Why?
|
| Comorbidity | 3 | 2023 | 10508 | 0.050 |
Why?
|
| Embolism, Air | 1 | 2001 | 110 | 0.050 |
Why?
|
| Rats, Inbred Strains | 3 | 1991 | 2088 | 0.050 |
Why?
|
| Eukaryotic Initiation Factor-4E | 1 | 2001 | 113 | 0.040 |
Why?
|
| CDC2 Protein Kinase | 1 | 2001 | 213 | 0.040 |
Why?
|
| Chromones | 1 | 2000 | 148 | 0.040 |
Why?
|
| Social Responsibility | 1 | 2003 | 386 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 8654 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2001 | 360 | 0.040 |
Why?
|
| DNA, Neoplasm | 1 | 2005 | 1745 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2001 | 5869 | 0.040 |
Why?
|
| Environment | 1 | 2006 | 1123 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2001 | 473 | 0.040 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2005 | 1135 | 0.040 |
Why?
|
| Chronic Disease | 3 | 2009 | 9318 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 4 | 2009 | 5492 | 0.040 |
Why?
|
| Reproducibility of Results | 7 | 2014 | 20098 | 0.040 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 2 | 2010 | 100 | 0.040 |
Why?
|
| Learning Curve | 1 | 2021 | 230 | 0.040 |
Why?
|
| Obesity, Morbid | 1 | 2010 | 1277 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2004 | 1510 | 0.040 |
Why?
|
| Probability | 2 | 2002 | 2477 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2001 | 477 | 0.040 |
Why?
|
| Mexico | 1 | 2022 | 764 | 0.040 |
Why?
|
| Transforming Growth Factor alpha | 1 | 1999 | 135 | 0.040 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 1991 | 361 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2005 | 8547 | 0.040 |
Why?
|
| Dipeptides | 1 | 2001 | 391 | 0.040 |
Why?
|
| Pyrrolidines | 1 | 2001 | 338 | 0.040 |
Why?
|
| DNA-Binding Proteins | 3 | 2002 | 9606 | 0.040 |
Why?
|
| Platelet Activating Factor | 1 | 1999 | 143 | 0.040 |
Why?
|
| DNA Fragmentation | 1 | 1999 | 237 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2014 | 3358 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2005 | 1509 | 0.040 |
Why?
|
| Laparotomy | 1 | 2000 | 457 | 0.040 |
Why?
|
| Mice, Inbred C3H | 2 | 1990 | 915 | 0.040 |
Why?
|
| Hepatic Artery | 1 | 1999 | 232 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2005 | 2224 | 0.040 |
Why?
|
| Reperfusion Injury | 2 | 2002 | 1023 | 0.040 |
Why?
|
| Biliary Tract | 2 | 1996 | 135 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2019 | 2850 | 0.040 |
Why?
|
| Communication Barriers | 1 | 2021 | 413 | 0.040 |
Why?
|
| Cyclin D1 | 1 | 2000 | 451 | 0.040 |
Why?
|
| Ibuprofen | 1 | 1999 | 229 | 0.040 |
Why?
|
| Interleukin-1 | 2 | 1993 | 1248 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2021 | 846 | 0.040 |
Why?
|
| Camptothecin | 1 | 2001 | 591 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2001 | 678 | 0.040 |
Why?
|
| Mice, Inbred Strains | 2 | 1990 | 1762 | 0.040 |
Why?
|
| Bile Acids and Salts | 1 | 1999 | 393 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2009 | 2373 | 0.040 |
Why?
|
| Morpholines | 1 | 2000 | 581 | 0.030 |
Why?
|
| Heart Transplantation | 4 | 1991 | 3233 | 0.030 |
Why?
|
| Kidney | 4 | 1997 | 7048 | 0.030 |
Why?
|
| Glucose Tolerance Test | 2 | 1990 | 1178 | 0.030 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 12463 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2002 | 5305 | 0.030 |
Why?
|
| Hospital Mortality | 3 | 2016 | 5294 | 0.030 |
Why?
|
| Cholecystography | 1 | 1996 | 42 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 2 | 2010 | 3595 | 0.030 |
Why?
|
| Gadolinium | 3 | 1990 | 960 | 0.030 |
Why?
|
| Nitrites | 1 | 1996 | 159 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 3 | 2001 | 411 | 0.030 |
Why?
|
| Abdomen | 3 | 2007 | 1128 | 0.030 |
Why?
|
| Abdominal Neoplasms | 1 | 1997 | 287 | 0.030 |
Why?
|
| Internationality | 1 | 2021 | 1001 | 0.030 |
Why?
|
| Organoids | 1 | 2022 | 740 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 1996 | 369 | 0.030 |
Why?
|
| Selection Bias | 1 | 2017 | 359 | 0.030 |
Why?
|
| Tyrosine | 2 | 2001 | 1440 | 0.030 |
Why?
|
| Bupivacaine | 1 | 2019 | 412 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2007 | 3466 | 0.030 |
Why?
|
| Intestinal Fistula | 1 | 1996 | 142 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2017 | 2915 | 0.030 |
Why?
|
| Vascular Neoplasms | 1 | 1997 | 166 | 0.030 |
Why?
|
| Insulin | 2 | 2005 | 6596 | 0.030 |
Why?
|
| Ischemia | 2 | 2001 | 1882 | 0.030 |
Why?
|
| Imidazoles | 1 | 2001 | 1180 | 0.030 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2000 | 621 | 0.030 |
Why?
|
| Computer Simulation | 2 | 2005 | 6240 | 0.030 |
Why?
|
| Neoplasms | 2 | 2001 | 22170 | 0.030 |
Why?
|
| Dogs | 2 | 1990 | 3839 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2020 | 803 | 0.030 |
Why?
|
| Perfusion | 1 | 1999 | 1373 | 0.030 |
Why?
|
| Retreatment | 1 | 2016 | 598 | 0.030 |
Why?
|
| Liver Function Tests | 2 | 2002 | 523 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2001 | 3615 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 1995 | 510 | 0.030 |
Why?
|
| Research | 1 | 2003 | 1982 | 0.030 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 2015 | 86 | 0.030 |
Why?
|
| Phosphatidylinositols | 1 | 1995 | 282 | 0.030 |
Why?
|
| Cost of Illness | 2 | 2015 | 1936 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2005 | 3702 | 0.030 |
Why?
|
| Protein Kinases | 1 | 2001 | 1608 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 2219 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 1998 | 1596 | 0.030 |
Why?
|
| Listeria monocytogenes | 1 | 1996 | 249 | 0.030 |
Why?
|
| Rhabdomyosarcoma | 1 | 1997 | 358 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 2001 | 2113 | 0.030 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 1990 | 1119 | 0.030 |
Why?
|
| Vena Cava, Inferior | 1 | 1997 | 458 | 0.030 |
Why?
|
| Health Care Rationing | 1 | 2016 | 437 | 0.030 |
Why?
|
| Acid-Base Equilibrium | 1 | 1993 | 181 | 0.030 |
Why?
|
| Young Adult | 6 | 2017 | 59243 | 0.030 |
Why?
|
| Diagnosis, Differential | 3 | 2018 | 12974 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2001 | 6228 | 0.030 |
Why?
|
| Leiomyosarcoma | 1 | 1997 | 422 | 0.030 |
Why?
|
| Pain | 1 | 2008 | 5073 | 0.030 |
Why?
|
| Models, Anatomic | 2 | 2009 | 683 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2001 | 3602 | 0.030 |
Why?
|
| Splenectomy | 1 | 2014 | 391 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2017 | 1813 | 0.030 |
Why?
|
| Appendectomy | 1 | 1996 | 433 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2001 | 2455 | 0.030 |
Why?
|
| Hernia, Ventral | 1 | 1996 | 218 | 0.030 |
Why?
|
| Benzophenanthridines | 2 | 2002 | 27 | 0.030 |
Why?
|
| Phenanthridines | 2 | 2002 | 51 | 0.030 |
Why?
|
| Mucin-2 | 1 | 2012 | 50 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2001 | 2057 | 0.020 |
Why?
|
| Philadelphia | 1 | 2012 | 266 | 0.020 |
Why?
|
| Mucin 5AC | 1 | 2012 | 96 | 0.020 |
Why?
|
| Models, Animal | 3 | 2003 | 2112 | 0.020 |
Why?
|
| Reference Values | 1 | 2019 | 4920 | 0.020 |
Why?
|
| Fluoroscopy | 1 | 1995 | 947 | 0.020 |
Why?
|
| 16,16-Dimethylprostaglandin E2 | 1 | 1991 | 22 | 0.020 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2017 | 801 | 0.020 |
Why?
|
| Rats, Inbred BUF | 4 | 1991 | 19 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2001 | 2872 | 0.020 |
Why?
|
| Cell Survival | 2 | 1999 | 5791 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 1991 | 862 | 0.020 |
Why?
|
| Cell Fractionation | 1 | 1991 | 251 | 0.020 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1991 | 509 | 0.020 |
Why?
|
| Accidental Falls | 1 | 2018 | 1068 | 0.020 |
Why?
|
| Polymyxin B | 1 | 1990 | 44 | 0.020 |
Why?
|
| Alkaloids | 2 | 2002 | 192 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2016 | 1139 | 0.020 |
Why?
|
| Macrophages, Alveolar | 1 | 1993 | 412 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 2 | 1990 | 6216 | 0.020 |
Why?
|
| Menstruation | 1 | 1992 | 307 | 0.020 |
Why?
|
| Injections, Intravenous | 2 | 1990 | 1379 | 0.020 |
Why?
|
| Extracorporeal Circulation | 2 | 2002 | 181 | 0.020 |
Why?
|
| Video Recording | 1 | 1995 | 966 | 0.020 |
Why?
|
| Blood Volume | 1 | 2011 | 547 | 0.020 |
Why?
|
| Transplantation, Homologous | 6 | 2002 | 4806 | 0.020 |
Why?
|
| Transplantation, Heterotopic | 1 | 1990 | 174 | 0.020 |
Why?
|
| Insulinoma | 1 | 2010 | 121 | 0.020 |
Why?
|
| Bile | 2 | 2001 | 298 | 0.020 |
Why?
|
| Autoradiography | 1 | 2010 | 728 | 0.020 |
Why?
|
| Unnecessary Procedures | 1 | 2013 | 415 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2018 | 2421 | 0.020 |
Why?
|
| Prevalence | 2 | 2019 | 15732 | 0.020 |
Why?
|
| Graft Enhancement, Immunologic | 1 | 1989 | 57 | 0.020 |
Why?
|
| Culture Media | 1 | 1991 | 897 | 0.020 |
Why?
|
| Pyridines | 1 | 2001 | 2875 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 931 | 0.020 |
Why?
|
| Digestive System | 1 | 1990 | 244 | 0.020 |
Why?
|
| Insurance, Liability | 1 | 2009 | 101 | 0.020 |
Why?
|
| Anesthesia, General | 1 | 1996 | 1174 | 0.020 |
Why?
|
| Lymphocyte Transfusion | 1 | 1989 | 232 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2001 | 4511 | 0.020 |
Why?
|
| Endothelium | 2 | 2001 | 765 | 0.020 |
Why?
|
| Fear | 1 | 2017 | 1476 | 0.020 |
Why?
|
| Benchmarking | 1 | 2015 | 1045 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2002 | 7594 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 2009 | 698 | 0.020 |
Why?
|
| Colon | 1 | 1996 | 1792 | 0.020 |
Why?
|
| Competency-Based Education | 1 | 2009 | 222 | 0.020 |
Why?
|
| Parathyroid Glands | 1 | 1989 | 518 | 0.020 |
Why?
|
| Insurance Carriers | 1 | 2009 | 156 | 0.020 |
Why?
|
| Indocyanine Green | 1 | 1989 | 233 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 1505 | 0.020 |
Why?
|
| Ultrasonography, Interventional | 1 | 1995 | 1496 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 1998 | 2645 | 0.020 |
Why?
|
| Mice | 5 | 2001 | 81525 | 0.020 |
Why?
|
| Mucin-1 | 1 | 2012 | 540 | 0.020 |
Why?
|
| Ovalbumin | 1 | 1989 | 677 | 0.020 |
Why?
|
| Tissue Donors | 2 | 2002 | 2331 | 0.020 |
Why?
|
| Cold Temperature | 2 | 2001 | 785 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 1989 | 587 | 0.020 |
Why?
|
| Critical Care | 2 | 2011 | 2696 | 0.020 |
Why?
|
| Choristoma | 1 | 1988 | 206 | 0.020 |
Why?
|
| Splanchnic Circulation | 1 | 2007 | 119 | 0.020 |
Why?
|
| Duodenum | 1 | 2010 | 490 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 2007 | 659 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 10766 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2002 | 8002 | 0.020 |
Why?
|
| Dumping Syndrome | 1 | 2005 | 18 | 0.020 |
Why?
|
| Diazoxide | 1 | 2005 | 52 | 0.020 |
Why?
|
| Adolescent | 4 | 2016 | 88319 | 0.020 |
Why?
|
| Risk Management | 1 | 2009 | 558 | 0.020 |
Why?
|
| Parenteral Nutrition | 1 | 2010 | 659 | 0.020 |
Why?
|
| Obesity | 2 | 2023 | 12947 | 0.020 |
Why?
|
| Miniaturization | 1 | 2005 | 153 | 0.020 |
Why?
|
| Mutation | 3 | 2000 | 30052 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2009 | 1572 | 0.020 |
Why?
|
| Organ Specificity | 1 | 1990 | 1967 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2011 | 1298 | 0.020 |
Why?
|
| Caffeine | 1 | 1989 | 700 | 0.010 |
Why?
|
| Malpractice | 1 | 2009 | 556 | 0.010 |
Why?
|
| Diet Therapy | 1 | 2005 | 151 | 0.010 |
Why?
|
| Body Weight | 3 | 1990 | 4618 | 0.010 |
Why?
|
| Stomach | 1 | 1988 | 696 | 0.010 |
Why?
|
| Esthetics | 1 | 2005 | 330 | 0.010 |
Why?
|
| Cholelithiasis | 2 | 1995 | 407 | 0.010 |
Why?
|
| Immunohistochemistry | 2 | 2012 | 11076 | 0.010 |
Why?
|
| Medical Errors | 1 | 2011 | 1263 | 0.010 |
Why?
|
| Health Status Indicators | 1 | 2008 | 970 | 0.010 |
Why?
|
| Movement | 1 | 2010 | 1478 | 0.010 |
Why?
|
| Genistein | 1 | 2002 | 86 | 0.010 |
Why?
|
| Anxiety | 1 | 2017 | 4573 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2005 | 1152 | 0.010 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2007 | 710 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2013 | 2775 | 0.010 |
Why?
|
| Insurance, Health | 1 | 2014 | 2498 | 0.010 |
Why?
|
| Intubation | 1 | 2002 | 139 | 0.010 |
Why?
|
| Kidney Transplantation | 1 | 1997 | 4234 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2007 | 1525 | 0.010 |
Why?
|
| Taurocholic Acid | 1 | 2001 | 43 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2010 | 4124 | 0.010 |
Why?
|
| Nitroprusside | 1 | 2001 | 272 | 0.010 |
Why?
|
| Cholagogues and Choleretics | 1 | 2001 | 39 | 0.010 |
Why?
|
| Analgesia | 1 | 2005 | 461 | 0.010 |
Why?
|
| Algorithms | 2 | 2015 | 14031 | 0.010 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2007 | 874 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 1990 | 22169 | 0.010 |
Why?
|
| Remote Consultation | 1 | 2003 | 237 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1989 | 4021 | 0.010 |
Why?
|
| Hemodynamics | 2 | 2002 | 4159 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 2007 | 1271 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1998 | 11528 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 1991 | 5486 | 0.010 |
Why?
|
| Succinate Dehydrogenase | 1 | 2000 | 145 | 0.010 |
Why?
|
| Medicare | 1 | 2018 | 6770 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 6814 | 0.010 |
Why?
|
| Reperfusion | 1 | 2000 | 271 | 0.010 |
Why?
|
| Feasibility Studies | 2 | 2000 | 5247 | 0.010 |
Why?
|
| Cyclosporins | 2 | 1989 | 216 | 0.010 |
Why?
|
| Prodrugs | 1 | 2001 | 261 | 0.010 |
Why?
|
| Norepinephrine | 1 | 2001 | 897 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 2001 | 603 | 0.010 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2001 | 373 | 0.010 |
Why?
|
| Organ Preservation | 1 | 2001 | 382 | 0.010 |
Why?
|
| Vascular Resistance | 1 | 2001 | 930 | 0.010 |
Why?
|
| Phosphatidylcholines | 1 | 1999 | 405 | 0.010 |
Why?
|
| Pressure | 1 | 2001 | 1154 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2009 | 2521 | 0.010 |
Why?
|
| Surgical Instruments | 1 | 2000 | 383 | 0.010 |
Why?
|
| Graft Rejection | 3 | 2002 | 4445 | 0.010 |
Why?
|
| Fellowships and Scholarships | 1 | 2005 | 1117 | 0.010 |
Why?
|
| Robotics | 1 | 2003 | 819 | 0.010 |
Why?
|
| Cysts | 2 | 1995 | 681 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1996 | 372 | 0.010 |
Why?
|
| Laparoscopes | 1 | 1996 | 37 | 0.010 |
Why?
|
| Deglutition Disorders | 1 | 2002 | 625 | 0.010 |
Why?
|
| Medical Illustration | 1 | 1997 | 135 | 0.010 |
Why?
|
| Esophagus | 1 | 2002 | 1033 | 0.010 |
Why?
|
| Curriculum | 1 | 2009 | 3743 | 0.010 |
Why?
|
| Liver Abscess | 1 | 1996 | 81 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2000 | 36426 | 0.010 |
Why?
|
| Phlebography | 1 | 1997 | 326 | 0.010 |
Why?
|
| Phospholipids | 1 | 1999 | 786 | 0.010 |
Why?
|
| Syndrome | 1 | 2002 | 3267 | 0.010 |
Why?
|
| Equipment Design | 1 | 2003 | 3510 | 0.010 |
Why?
|
| Blood Glucose | 1 | 1990 | 6391 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 2003 | 1881 | 0.010 |
Why?
|
| Electrocoagulation | 1 | 1995 | 152 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1981 | 3076 | 0.010 |
Why?
|
| Oligopeptides | 1 | 1981 | 1187 | 0.010 |
Why?
|
| Ultraviolet Rays | 2 | 1990 | 1080 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1999 | 1085 | 0.010 |
Why?
|
| Listeriosis | 1 | 1996 | 149 | 0.010 |
Why?
|
| Organ Size | 2 | 1990 | 2254 | 0.010 |
Why?
|
| Punctures | 1 | 1996 | 366 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 1999 | 1699 | 0.010 |
Why?
|
| Disease Progression | 1 | 2011 | 13506 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2001 | 1866 | 0.010 |
Why?
|
| Sphincterotomy, Endoscopic | 1 | 1994 | 44 | 0.010 |
Why?
|
| Surgical Mesh | 1 | 1996 | 311 | 0.010 |
Why?
|
| Salicylic Acid | 1 | 1993 | 62 | 0.010 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 1996 | 662 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1997 | 13380 | 0.010 |
Why?
|
| Salicylates | 1 | 1993 | 127 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 7407 | 0.010 |
Why?
|
| Genitalia, Female | 1 | 1992 | 147 | 0.010 |
Why?
|
| Mice, SCID | 1 | 1996 | 2626 | 0.010 |
Why?
|
| Child | 2 | 1996 | 80153 | 0.010 |
Why?
|
| Cholesterol | 1 | 1999 | 2904 | 0.010 |
Why?
|
| Microbial Collagenase | 1 | 1990 | 112 | 0.010 |
Why?
|
| Recurrence | 1 | 2002 | 8465 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1981 | 13446 | 0.010 |
Why?
|
| Aorta | 1 | 1997 | 2042 | 0.000 |
Why?
|
| Transplantation, Isogeneic | 1 | 1989 | 248 | 0.000 |
Why?
|
| Gene Deletion | 1 | 1996 | 2665 | 0.000 |
Why?
|
| Histocompatibility Antigens | 1 | 1989 | 464 | 0.000 |
Why?
|
| Intensive Care Units | 1 | 2000 | 3745 | 0.000 |
Why?
|
| Transplantation Immunology | 1 | 1989 | 532 | 0.000 |
Why?
|
| Immunization | 1 | 1990 | 1228 | 0.000 |
Why?
|
| Skin Transplantation | 1 | 1991 | 1083 | 0.000 |
Why?
|
| Blood Pressure | 1 | 2001 | 8481 | 0.000 |
Why?
|
| Cyclophosphamide | 1 | 1989 | 2218 | 0.000 |
Why?
|
| Endometriosis | 1 | 1992 | 870 | 0.000 |
Why?
|
| Internship and Residency | 1 | 2003 | 5880 | 0.000 |
Why?
|
| Acute Disease | 1 | 1994 | 7237 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 2002 | 18252 | 0.000 |
Why?
|
| Lymphocytes | 1 | 1989 | 2612 | 0.000 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1997 | 9280 | 0.000 |
Why?
|
| Pregnancy | 1 | 1995 | 29874 | 0.000 |
Why?
|
| Infant | 1 | 1988 | 36192 | 0.000 |
Why?
|